LENZ Therapeutics Inc LENZ

Morningstar Rating
$5.18 +0.30 (6.15%)
View Full Chart

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

LENZ is trading at a LOCK|#$!<N premium.
Price
$5.18
Fair Value
LOCK|W<##Z%r
Uncertainty
LOCK|&H #w$m
1-Star Price
LOCK|.#%d>b>H
5-Star Price
LOCK|zv^#rlF
Economic Moat
LOCK|!XC
Capital Allocation

Trading Information

Previous Close Price
$4.88
Day Range
$4.885.20
52-Week Range
$4.6850.40
Bid/Ask
$5.00 / $5.41
Shares Outstanding
31.35M
Market Cap
$162.42M
Volume/Avg
1M / 884,275

Key Statistics

Price/Earnings (Normalized)
Price/Sales
7.35
Dividend Yield (Trailing)
0.00%
Dividend Yield (Forward)
0.00%
Total Yield

Company Profile

LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products. Its products VIZZ (aceclidine ophthalmic solution) 1.44% is a once-daily eye drop developed to restore clear near vision for up to 10 hours. VIZZ is powered by aceclidine, highlighted by its differentiated mechanism of action as a predominantly pupil-selective miotic that interacts with the iris, with minimal ciliary muscle stimulation.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Core
Total Number of Employees
152

Valuation

Metric
LENZ
Price/Earnings (Normalized)
Price/Book Value
0.66
Price/Sales
7.35
Price/Cash Flow
Price/Earnings
No chart available

Financial Strength

Metric
LENZ
Quick Ratio
10.03
Current Ratio
10.40
Interest Coverage
Quick Ratio
LENZ

Profitability

Metric
LENZ
Return on Assets (Normalized)
−39.20%
Return on Equity (Normalized)
−42.15%
Return on Invested Capital (Normalized)
−46.45%
Return on Assets
LENZ

Biotechnology Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Vertex Pharmaceuticals Inc
VRTX
LOCK|^Q>SswlLOCK|$%?h$123B
Regeneron Pharmaceuticals Inc
REGN
LOCK|%#gPB@LOCK|SvB%$71B
argenx SE ADR
ARGX
LOCK|@!?t@gLOCK|<c$54B
BeOne Medicines Ltd ADR
ONC
LOCK|>#^Y<H>LOCK|^^$36B
Alnylam Pharmaceuticals Inc
ALNY
LOCK|X??&tCLOCK|WR%g$36B
Royalty Pharma PLC Class A
RPRX
LOCK|>l@$g#&LOCK|^K^B!$26B
Moderna Inc
MRNA
LOCK|#x%x?$LOCK|tM?$25B
Incyte Corp
INCY
LOCK|?pFF>>vLOCK|>n&$23B
BioNTech SE ADR
BNTX
LOCK|@PjHvlLOCK|!qw$23B
BridgeBio Pharma Inc
BBIO
LOCK|$<T#zPLOCK|G@$16B

Sponsor Center